Pancrelipase: an evidence-based review of its use for treating pancreatic exocrine insufficiency

Kei Nakajima1
Haruki Oshida1
Toshitaka Muneyuki2
Masafumi Kakei2

1Division of Clinical Nutrition, Department of Medical Dietetics, Faculty of Pharmaceutical Sciences, Josai University, Keyakidai, Sakado, Japan
2First Department of Comprehensive Medicine, Saitama Medical Center, Jichi Medical University School of Medicine, Amanuma, Omiya, Saitama, Japan

Abstract: Pancreatic exocrine insufficiency (PEI) is often observed in patients with pancreatic diseases, including chronic pancreatitis, cystic fibrosis, and tumors, or after surgical resection. PEI often results in malnutrition, weight loss and steatorrhea, which together increase the risk of morbidity and mortality. Therefore, nutritional interventions, such as low-fat diets and pancreatic enzyme replacement therapy (PERT), are needed to improve the clinical symptoms, and to address the pathophysiology of pancreatic exocrine insufficiency. PERT with delayed-release pancrelipase is now becoming a standard therapy for pancreatic exocrine insufficiency because it significantly improves the coefficients of fat and nitrogen absorption as well as clinical symptoms, without serious treatment-emergent adverse events. The major adverse events were tolerable gastrointestinal tract symptoms, such as stomach pain, nausea, and bloating. Fibrosing colonopathy, a serious complication, is associated with high doses of enzymes. Several pancrelipase products have been approved by the US Food and Drug Administration in recent years. Although many double-blind, placebo-controlled trials of pancrelipase products have been conducted in recent years, these studies have enrolled relatively few patients and have often been less than a few weeks in duration. Moreover, few studies have addressed the issue of pancreatic diabetes, a type of diabetes that is characterized by frequent hypoglycemia, which is difficult to manage. In addition, it is unclear whether PERT improves morbidity and mortality in such settings. Therefore, large, long-term prospective studies are needed to identify the optimal treatment for pancreatic exocrine insufficiency. The studies should also examine the extent to which PERT using pancrelipase improves mortality and morbidity. The etiology and severity of pancreatic exocrine insufficiency often differ among patients with gastrointestinal diseases or diabetes (type 1 and type 2), and among elderly subjects. Finally, although there is currently limited clinical evidence, numerous extrapancreatic diseases and conditions that are highly prevalent in the general population may also be considered potential targets for PERT and related treatments.

Keywords: pancreatic exocrine insufficiency, chronic pancreatitis, pancreatic diabetes, steatorrhea, pancreatic enzyme replacement therapy, extrapancreatic diseases

Core evidence Clinical impact summary for pancrelipase and pancreatic exocrine insufficiency

<table>
<thead>
<tr>
<th>Outcome measure</th>
<th>Evidence</th>
<th>Implications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Disease-oriented evidence</td>
<td>Randomized, double-blind, placebo-controlled trials showed that pancreatic enzyme replacement therapy with pancrelipase even for short periods of a few weeks improved steatorrhea and the coefficient of fat absorption and of nitrogen absorption along with increase in</td>
<td>Pancrelipase improves maldigestion and malnutrition, which leads to restoration of nutritional conditions, irrespective of age</td>
</tr>
</tbody>
</table>
**Introduction**

The pancreas is a major organ that regulates food digestion and absorption in harmonization with other organs. Pancreatic diseases are associated with deterioration of the pancreatic parenchyma and of the dual physiological functions of pancreas (ie, its exocrine and endocrine functions). This deterioration occurs over several years to decades, and involves atrophic/fibrotic changes that ultimately result in pancreatic exocrine insufficiency (PEI) and pancreatic endocrine insufficiency (eg, pancreatic diabetes).\(^1\)\(^-\)\(^5\)

PEI is often observed in individuals with chronic pancreatitis, cystic fibrosis, and pancreatic tumors, or after surgical resection of the pancreas (Figure 1).\(^1\)\(^-\)\(^4\) During progression of pancreatic disease, PEI is associated with malnutrition, including low levels of micronutrients and fat-soluble vitamins, particularly vitamin D, and essential fatty acids, coupled with gradual weight loss and steatorrhea as a result of maldigestion. This issue is particularly important in children because malnutrition may affect growth patterns. Therefore, lifestyle (eg, cessation of alcohol and smoking), nutritional (eg, low-fat diet and dietary supplementation with essential minerals and vitamins), and pharmacological interventions are needed to improve the clinical symptoms and pathophysiology of pancreatic diseases. For example, pancreatic enzyme replacement therapy (PERT) not only improves the clinical symptoms and malnutrition caused by PEI, but can also allow the patient to discontinue a low-fat diet.

This review summarizes the current evidence for the effectiveness of PERT with pancrelipase products approved for different indications, referring to literature indexed in PubMed. We also discuss use of the available pancrelipase products for treating PEI caused predominantly by pancreatic diseases. We also describe the potential use of PERT with pancrelipase for treating various extrapancreatic conditions.

**Pancrelipase products approved for PERT**

PERT using pancrelipase products, which are mostly purified from the porcine pancreas, have been tested extensively for PEI associated with pancreatic diseases.\(^4\)\(^-\)\(^9\) Pancreatic enzyme products have been available as over-the-counter drugs in many countries, including the US and Europe (eg, France, Germany, Italy, Spain, and the UK) for several decades.\(^8\) However, because of the potential adverse effects and limited effectiveness, some drug regulatory agencies, including the US Food and Drug Administration (FDA), have required the manufacturers to obtain regulatory approval before they can market their products.

Many pancrelipase products have been introduced to treat PEI. Two of these products, pancrelipase and pancreatin, are the major pancreatic enzymes produced in the porcine pancreas, with pancrelipase showing greater expression.\(^8\) Although several reports have suggested that bovine enzyme products may offer an alternative to porcine enzymes, bovine enzymes are still rarely used in many countries because their lipase activity is approximately 75% lower than that of the corresponding porcine enzymes.\(^8\) Pancreatic exocrine enzymes manufactured by gene transfer techniques may soon replace animal-derived enzymes and are currently under clinical development.

Of the three major pancreatic enzymes, lipase is the most susceptible to loss or degradation after administration. Current therapeutic concepts recommend the administration
of 25,000–50,000 units of porcine lipase per meal, when administered using pH-sensitive pancreatin microspheres, or 20,000–25,000 units for snacks. These doses may be increased by up to three-fold until sufficient clinical improvements are observed. The administration of bicarbonate or acid suppressers, preferably proton pomp inhibitors, is often necessary to prevent acid-mediated inactivation of enzymes, although enteric-coated enzyme products are increasingly being used to avoid this problem. If the response remains inadequate, bacterial overgrowth in the small intestine should be considered and treated.

Currently, all of the enzyme products used for PERT are of porcine origin. Therefore, it is possible that allergic reactions can occur, including anaphylactic shock, and their use in patients at high risk for such reactions should be carefully monitored.

As of April 2012, the FDA has approved five PERT products that meet the regulatory standards for quality, safety, and effectiveness. Although clinical trials with pancrelipase and pancreatin were conducted before FDA approval, several pancrelipase products, including Creon®, have been approved for marketing in the US since 2009 (Table 1). Pancrecarb® which consists of a delayed-release capsule and enteric-coated microspheres, as of April 2012 was awaiting FDA approval. In Japan, Lipacreon® was the first pancreatic digestive enzyme replacement drug to be

Table 1 Available pancrelipase products approved by the US Food and Drug Administration

<table>
<thead>
<tr>
<th>Drug</th>
<th>Active ingredients</th>
<th>Time of FDA approval</th>
<th>Strength (amylase, lipase, and protease)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Creon®</td>
<td>Capsule, delayed release; oral</td>
<td>2009</td>
<td>30,000 USP U; 6000 USP U; 19,000 USP U; 60,000 USP U; 12,000 USP U; 38,000 USP U; 120,000 USP U; 24,000 USP U; 76,000 USP U; 27,000 USP U; 5000 USP U; 17,000 USP U; 55,000 USP U; 10,000 USP U; 34,000 USP U; 82,000 USP U; 15,000 USP U; 51,000 USP U; 109,000 USP U; 20,000 USP U; 68,000 USP U</td>
</tr>
<tr>
<td>Zenpep®</td>
<td>Capsule, delayed release, oral</td>
<td>2009</td>
<td>17,500 USP U; 4200 USP U; 10,000 USP U; 43,750 USP U; 10,500 USP U; 25,000 USP U; 61,000 USP U; 21,000 USP U; 37,000 USP U; 70,000 USP U; 16,800 USP U; 40,000 USP U</td>
</tr>
<tr>
<td>Pancreaze®</td>
<td>Capsule, delayed release, oral</td>
<td>2010</td>
<td>27,600 USP U; 13,800 USP U; 27,600 USP U; 41,400 USP U; 20,700 USP U; 41,400 USP U; 46,000 USP U; 23,000 USP U; 46,000 USP U</td>
</tr>
<tr>
<td>Ultresa®</td>
<td>Capsule, delayed release, oral</td>
<td>2012</td>
<td>39,150 USP U; 10,440 USP U; 39,150 USP U; 78,300 USP U; 28,880 USP U; 78,300 USP U</td>
</tr>
<tr>
<td>Viokace®</td>
<td>Tablet, oral</td>
<td>2012</td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: FDA, Food and Drug Administration; USP U, United States Pharmacopeia units.
approved by the Ministry of Health, Labour, and Welfare in 2011 for PEI caused by chronic pancreatitis, pancreatic resection, cystic fibrosis, and other conditions.

Overall, many clinical trials of pancrelipase products approved by the FDA have been conducted in recent years. These studies have shown various degrees of improvement in steatorrhea and malnutrition with a low risk of adverse effects, including tolerable gastrointestinal tract symptoms, in patients with chronic pancreatitis, cystic fibrosis, and pancreatic resection (Table 2). However, most of these studies enrolled relatively few patients and were often less than a few weeks in length. Moreover, few studies have addressed the issue of pancreatic diabetes, another clinical aspect of chronic pancreatitis and cystic fibrosis, which is likely to be affected by PERT through increased absorption of carbohydrates. It is also unknown whether PERT using pancrelipase products improves morbidity and mortality, which should be examined in long-term prospective clinical studies.

Another issue regarding the use of PERT is that, contrary to initial expectations, PEI is a highly heterogeneous disease. As shown in Figure 2, PEI is also observed in patients with extrapancreatic diseases and conditions, gastrointestinal diseases, diabetes (both type 1 and type 2), and in the elderly. In particular, the prevalence of extrapancreatic diseases (eg, type 2 diabetes) and associated conditions in elderly individuals is substantially higher than those of “traditional” pancreas diseases, considering that chronic pancreatitis is detected in 0.04%–5% of all autopsies, and cystic fibrosis is a rare genetic disease. Furthermore, the prevalence of extrapancreatic diseases and conditions is rapidly increasing worldwide because of the obesity pandemic and prolonged longevity. Although these emerging PEIs are likely to predispose to malnutrition and increased risk of morbidity and/or mortality, the clinical relevance and application of PERT for these conditions have not been fully examined. Therefore, animal and clinical studies are needed to explore fully the underlying mechanisms and to determine the need for improving nutritional status and effects on morbidity/mortality in people with diabetes or gastrointestinal diseases, and in elderly individuals.

**Detection of PEI in routine clinical practice**

It is often difficult to detect PEI in routine clinical practice, particularly because patients are usually asymptomatic in the early stage of PEI. In addition, there is some controversy regarding the clinical applicability of the methods used to diagnose PEI. Nevertheless, for effective PERT, it is important to detect PEI as early and properly as possible. In principle, the diagnosis of PEI should be based on standard methods such as the secretin-pancreozymin test or endoscopy. Other functional tests, including quantification of fat absorption and the $^{13}$C-mixed triglyceride breath test, are also useful to determine PEI associated with malabsorption. Several noninvasive and inexpensive tests, such as measurement of fecal elastase-1 concentrations, are also useful to determine reduced pancreatic secretion in patients with different pancreatic diseases. Fecal elastase-1 is a proteolytic enzyme secreted exclusively from the pancreas. However, false-positive results are often observed in patients with intestinal diseases and diarrhea, presumably because of dilutional effects. In most cases, measuring the fecal concentrations of elastase (fecal elastase-1) may be sufficient to detect PEI, because elastase concentrations show higher sensitivity for PEI compared with chymotrypsin concentrations. Fecal elastase-1 concentration may be considered as a standard clinical marker for PEI, particularly moderate to severe PEI.

However, clinicians must be aware that abnormal concentrations of these markers may reflect advanced stages of PEI. In addition, clinical symptoms such as steatorrhea may not occur until more than 90% of the pancreatic parenchyma is lost. Therefore, replacing ≥10% of endogenous pancreatic enzymes is required for food digestion and may be sufficient to manage the clinical symptoms.

**Pancreatic diseases and PERT**

**Chronic pancreatitis**

Chronic pancreatitis is characterized by irreversible destruction of pancreatic tissue, and results in pancreatic exocrine and endocrine insufficiency. In developed countries, alcohol is responsible for up to 80% of cases of chronic pancreatitis in adults. Although smoking has received less attention than alcohol in terms of understanding the pathogenesis of chronic pancreatitis, smoking is also associated with chronic pancreatitis, pancreatic calcification, and PEI, even after adjusting for alcohol intake and other risk factors. In fact, we showed that current smoking was significantly associated with low serum amylase, a possible marker for pancreatic exocrine dysfunction, in a general population. Therefore, drinking of alcohol and smoking, including past smoking, may contribute to the development and progression of chronic pancreatitis and PEI. In children, genetic and anatomic factors seem to contribute to the pathogenesis of chronic pancreatitis.

Although therapies for chronic pancreatitis include opioids, endoscopy, and surgery, standard treatment for PEI consists of PERT along with dietary interventions.
<table>
<thead>
<tr>
<th>Drug</th>
<th>Study</th>
<th>Study design/duration/number of subjects</th>
<th>Disease</th>
<th>Results</th>
<th>Adverse effects</th>
</tr>
</thead>
<tbody>
<tr>
<td>Creon®</td>
<td>Safdi et al</td>
<td>DBRPC, 2 weeks, 27 adults (Creon, n = 14; placebo, n = 13)</td>
<td>Chronic pancreatitis</td>
<td>Change in CFA was significantly greater with pancrelipase versus placebo (36.7% and 12.1%); tool consistency/frequency, and fat excretion improved significantly in pancrelipase-treated patients</td>
<td>Six TEAEs occurred in 3 subjects treated with pancrelipase treatment versus placebo; there was no evidence of hyperuricemia</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Whitcomb</td>
<td>et al</td>
<td>DBRPC, 1 week, 54 adults (Creon, n = 25; placebo, n = 29)</td>
<td>Chronic pancreatitis</td>
<td>Changes from baseline in CFA (31.9% versus 8.7%; P &lt; 0.0001) and CAN (35.2% versus 8.9%; P = 0.0005) were significantly greater with pancrelipase versus placebo</td>
<td>TEAEs were reported in 5 patients (20.0%) treated with pancrelipase versus placebo; the most common events were gastrointestinal events and metabolism/nutrition disorders</td>
</tr>
<tr>
<td>Gubergrits</td>
<td>et al</td>
<td>Open-label, 6 months, 48 adults</td>
<td>Chronic pancreatitis</td>
<td>Body weight increased by 2.7 ± 3.4 kg (P &lt; 0.0001) and daily stool frequency decreased by −1.0 ± 1.3 (P &lt; 0.001); increase in body weight was greater in lean patients (BMI &lt; 18.5 kg/m²) than in patients with a BMI &gt; 18.5 kg/m²</td>
<td>Four patients (7.8%) experienced treatment-related AEs</td>
</tr>
<tr>
<td>Stern</td>
<td>et al</td>
<td>DBRPC, 1 week, 36 adults (Creon, n = 18; placebo, n = 18), 38 pediatric/adolescent patients (Creon, n = 18; placebo, n = 20)</td>
<td>Cystic fibrosis</td>
<td>CFA decreased significantly (P &lt; 0.001) with placebo (adults, 36.9%; pediatric/adolescents, 34.9%) from the open-label to double-blind phase of the study, while no change was observed in pancrelipase-treated patients (adults, 2%; pediatric/adolescents, 3.25%)</td>
<td>One serious AE occurred, ie, hospitalization for pulmonary exacerbation.</td>
</tr>
<tr>
<td>Trapnell</td>
<td>et al</td>
<td>DBRPC, 5-day, two-way crossover, 32 patients, (Creon, n = 16; placebo, n = 16)</td>
<td>Cystic fibrosis</td>
<td>Mean CFA (88.6% versus 49.6%; P &lt; 0.01) and CNA (85.1% versus 49.9%; P &lt; 0.001) were significantly greater with pancrelipase versus placebo</td>
<td>Symptom improvement was greater with pancrelipase than placebo; fewer patients treated with pancrelipase (18.8%) reported TEAEs than patients treated with placebo (38.7%); the most common TEAEs were gastrointestinal disorders (eg, abdominal pain and flatulence)</td>
</tr>
<tr>
<td>Colombo</td>
<td>et al</td>
<td>Open-label, 2 weeks, 12 infants</td>
<td>Cystic fibrosis</td>
<td>Pancrelipase significantly increased mean CFA from 58.0% at baseline to 84.7% (P = 0.0013); pancrelipase also significantly decreased mean stool fat excretion (from 13.3 to 5.3 g/day; P = 0.001)</td>
<td>Pancrelipase was well tolerated and decreased fat malabsorption; no serious AEs were reported</td>
</tr>
<tr>
<td>Graff</td>
<td>et al</td>
<td>DBRPC, 5 days, two-way crossover, 16 children aged 7–11 years</td>
<td>Cystic fibrosis</td>
<td>Mean (SE) CFA was significantly greater with pancrelipase versus placebo (82.8% [2.7%] versus 47.4% [2.7%]; P &lt; 0.001); pancrelipase significantly improved stool fat, weight, and nitrogen, and significantly reduced daily stool frequency (all, P &lt; 0.001)</td>
<td>TEAEs were reported in 5 patients (29.4%) treated with pancrelipase and in 9 patients (56.3%) treated with placebo; the most common AEs were gastrointestinal disorders; there were no serious AEs</td>
</tr>
<tr>
<td>Drug</td>
<td>Study</td>
<td>Study design/duration/number of subjects</td>
<td>Disease</td>
<td>Results</td>
<td>Adverse effects</td>
</tr>
<tr>
<td>-----------</td>
<td>-------------------------------</td>
<td>----------------------------------------------------------------------------------------------------------</td>
<td>--------------------------</td>
<td>------------------------------------------------------------------------</td>
<td>---------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Zenpep®</td>
<td>Toskes et al</td>
<td>DBR, dose-response, crossover, ≤6 days 72 adults (available CFA values)</td>
<td>Chronic pancreatitis</td>
<td>CFA was higher in patients treated with low-dose (88.9%) and high-dose (89.9%) pancrelipase versus placebo (82%; P &lt; 0.001; n = 72) with no difference between doses (P = 0.228); CNA (P &lt; 0.001), body weight (P ≤ 0.021), and BMI (P = 0.020) also increased with both doses of pancrelipase compared with baseline</td>
<td>Percentage of days with PEI symptoms decreased with both doses</td>
</tr>
<tr>
<td></td>
<td>Wooldridge et al</td>
<td>DBRPC, crossover 1 week, open-label, 2 weeks, 33 adults</td>
<td>Cystic fibrosis</td>
<td>CFA (88.3% versus 62.8%; P &lt; 0.001) and CNA (87.2% versus 65.7%; P &lt; 0.001) were significantly greater with pancrelipase versus placebo</td>
<td>Nineteen patients (56%) treated with pancrelipase and 16 patients (50%) treated with placebo experienced ≥ 1 TEAE; there were no serious TEAEs</td>
</tr>
<tr>
<td>Pancreaze®</td>
<td>Trapnell et al</td>
<td>DBRPC, 1 week 26 adults and 14 pediatric patients (Pancreaze, n = 20; placebo, n = 20)</td>
<td>Cystic fibrosis</td>
<td>Mean changes in CFA (~1.5% ± 5.9% versus −34.1% ± 23.0%; P &lt; 0.001) and CNA (1.3% ± 4.7% versus −26.5% ± 15.3%; P &lt; 0.001) were significantly smaller with pancrelipase versus placebo</td>
<td>TEAEs were reported in 8 patients (40%) treated with pancrelipase and in 12 patients (60%) treated with placebo; the most common AEs were gastrointestinal disorders; no unexpected AEs were reported</td>
</tr>
</tbody>
</table>

**Notes:** CFA (%) = [(fat intake grams – fat exertion grams)/fat intake grams] × 100; CNA (%) = [(nitrogen intake grams – nitrogen exertion grams)/nitrogen intake grams] × 100.

**Abbreviations:** DBRPC, double-blind, randomized, placebo-controlled trial; DBR, double-blind, randomized trial; TEAEs, treatment-emergent adverse events; AE, adverse event; CFA, coefficient of fat absorption; CNA, coefficient of nitrogen absorption; BMI, body mass index; SE, standard error of the mean.
In terms of specific pharmacotherapies, two double-blind, randomized, placebo-controlled studies by Safdi et al and Whitcomb et al revealed that pancrelipase (Creon) substantially improved clinical symptoms, including stool consistency and abdominal pain, in patients with chronic pancreatitis (Table 2). In a recent open-label clinical trial, the administration of delayed-release pancrelipase capsules (Creon) resulted in significant weight gain and reduced stool frequency in 48 patients with PEI caused by chronic pancreatitis or pancreatic surgery. Similarly, treatment with low-dose Zenpep®×5000 lipase units/day significantly increased the coefficients of fat absorption and nitrogen absorption in patients with chronic pancreatitis.

Based on these and other studies, several pancrelipase products are now being used to treat PEI associated with chronic pancreatitis and other diseases. There are no marked differences in the cost of the currently available products. In addition, treatment-emergent adverse events observed in clinical trials of PERT, which were mostly mild and tolerable gastrointestinal symptoms such as abdominal pain were generally similar to those observed with placebo.

Worryingly, the mortality rate of patients with chronic pancreatitis is 3–4-fold higher than that of the general population, while the 20-year survival rate is less than 50%. Clinical studies examining the effects of pancrelipase on long-term mortality are currently lacking, and long-term double-blind, randomized, placebo-controlled studies, if possible, are needed to determine whether pancrelipase reduces the risk of mortality in addition to improving clinical symptoms in patients with PEI caused by chronic pancreatitis.

Cystic fibrosis
PEI occurs in approximately 85% of patients with cystic fibrosis. Cystic fibrosis is a rare autosomal recessive disease that affects pancreatic function and lung function from birth. In cystic fibrosis, the secretion of thick mucus is increased in the lungs and pancreas, eventually leading to dyspnea and blocking the secretion of pancreatic enzymes. The condition is caused by mutations in a single gene on chromosome 7, which encodes the cystic fibrosis transmembrane conductance regulator.

Standard therapy for cystic fibrosis includes chest physical therapy, aerosolized antibiotics, mucus-thinning drugs, and PERT. In addition, people with cystic fibrosis are recommended to increase their intake of calories, protein, fat, and appropriate minerals and vitamins. Patients with cystic fibrosis are at increased risk of malnutrition as a result of nutrient malabsorption, leading to growth failure in children. On this basis, PERT is essential for children and young patients with cystic fibrosis.

Several double-blind, randomized, placebo-controlled studies and an open-label study have shown that treatment with pancrelipase products (eg, Creon, Zenpep, Pancreaze®) improves the coefficients of fat and nitrogen absorption and clinical symptoms in patients with cystic fibrosis compared with placebo, with favorable safety profiles (Table 2). In a double-blind crossover trial by Wooldridge et al, a higher
coefficient of fat absorption were observed during the pancrelipase period compared with placebo, particularly in patients with a lower coefficient of fat absorption at baseline (Figure 3). In addition, pancrelipase improved fat absorption, as shown by a significantly lower change in the coefficient of fat absorption between the open-label and double-blind phases for pancrelipase (−1.5% ± 5.9%; P < 0.001) compared with placebo (−34.1% ± 23.0%, Figure 4). Thus, pancrelipase products are likely to improve PEI secondary to cystic fibrosis.

Olveira and Olveira reported that most patients with PEI can tolerate high-fat diets providing they are treated with appropriate doses of pancreatic enzymes. These results suggest that low-fat diets may not be necessary when nutrient malabsorption has been corrected with appropriate PERT. They also noted that if nutritional goals are not achieved or maintained with dietary modifications, supplements may be added to improve nutritional status, including via enteral or parenteral nutritional support where necessary.

Pancreatic resection
Partial or total pancreatectomy immediately causes PEI, meaning PERT is essential to maintain adequate digestion. Partial pancreatectomy is sometimes carried out in patients with chronic pancreatitis and intolerance to pain, in those with evidence of necrosis in pancreatic tissue, and in patients with a pancreatic tumor. Similar to PEI in patients with chronic pancreatitis or cystic fibrosis, PEI occurring after pancreatectomy can be treated with pancrelipase products, with good tolerability.

Enteral nutrition
The studies described above suggest that PERT is likely to improve clinical symptoms and malnutrition, irrespective of the clinical manifestations and cause of PEI. However, in clinical practice, PERT may be necessary for patients who are unable to swallow tablets, capsules, or granules. In such cases, enteral feeding tubes can be used to administer the pancreatic enzymes. Indeed, Ferrie et al reported that pancreatic enzyme supplementation can continue during enteral feeding via gastric tubes. In addition, Shlieout et al reported that pancrelipase capsules (Creon) can be mixed with baby food at pH < 4.5 and administered via gastric tubes without clogging, sticking, or visible pellet damage, and without loss of gastric resistance or lipase activity. These results suggest that PERT can be performed during enteral nutrition.

Adverse effects of pancrelipase
Although some gastrointestinal events were observed in individuals who received pancrelipase, no serious adverse effects were observed in recent clinical trials (Table 2). The major adverse effects included stomach pain, nausea, bloating, headache, and dizziness. Although hyperuricemia was reported in patients with cystic fibrosis treated with pancreatic enzyme products, the most recent studies have found no significant association between the use of pancrelipase and hyperuricemia. Fibrosing colonopathy, a serious complication of cystic fibrosis, can develop several months to several years after starting high-dose PERT. Generally, high doses of enzymes (eg, >75,000 units/meal for adults and >25,000 units/meal for children) are not recommended, nor are doses of lipase >2500 units/kg/meal (10,000 units/kg/day). The Cystic Fibrosis Foundation recommended in their consensus-based guidelines that dosages should be limited to 500–2500 lipase units/kg/meal, <10,000 lipase units/kg/day, or <4000 lipase units/g dietary fat/day. Although the pathogenesis of fibrosing colonopathy is unknown, it is highly correlated with recent studies.
with pancreatic enzyme dose, the clinical features of Crohn’s disease, and ischemic bowel disease, and compounds present in enteric coatings designed to protect the enzymes against gastric acid. Lee et al also proposed that local injury caused by proteases or immune activity may be responsible for the pathological changes in fibrosing colonopathy.

**Pancreatic diabetes as a complication of pancreatic disease**

It is well known that pancreatic disorders (eg, chronic pancreatitis, cystic fibrosis, and pancreatic surgical resection) cause endocrine dysfunction, known as pancreatic diabetes, through the progressive destruction of pancreatic tissue (Figure 1). Kahl and Malfertheiner reported that hypoglycemia is particularly difficult to manage after total pancreatectomy. Except for pancreatic resection, the etiology of pancreatic diabetes is not fully understood, probably because of its complicated phenotype and pathophysiology in comparison with type 1 and type 2 diabetes. In pancreatic diabetes, secretion of pancreatic endocrine hormones (ie, insulin, glucagon, and pancreatic polypeptide) is impaired, eventually resulting in brittle diabetes associated with hyperglycemia and frequent hypoglycemia (Table 3). Since people with pancreatic diabetes are often nonobese or lean with malnutrition, they are occasionally misdiagnosed and treated with inappropriate drugs and diet. Pancreatic diabetes may be more common than currently believed, accounting for up to 9% of all cases of diabetes. By contrast, a nationwide study in Japan showed that pancreatic diabetes accounted for 0.8% of patients with total diabetes. There might also be a racial difference in the prevalence of pancreatic diabetes.

In moderate to advanced pancreatic diabetes, insulin injection is necessary to treat hyperglycemia. However, this may result in sudden hypoglycemia because of insufficient glucagon secretion and the absence of peripheral insulin resistance. Surprisingly, hepatic insulin resistance is quite common in patients with pancreatic diabetes associated with chronic pancreatitis. Hepatic insulin resistance results in upregulated hepatic glucose production and impaired hepatic glucose disposal.
Unfortunately, it is unknown whether PERT improves the pathophysiology of pancreatic diabetes because no clinical trials have tested this possibility. PERT with pancrelipase increases fat, protein, and carbohydrate absorption. Therefore, PERT is expected to worsen glucose metabolism by increasing glucose transport from intestine to the circulation. Consistently, the prescribing information for Creon, which is manufactured by Abbott Laboratories (North Chicago, IL), lists “blood sugar increase (hyperglycemia) or decrease (hypoglycemia)” as a common side effect. However, increased glucose absorption could reduce the risk of hypoglycemia, allowing more aggressive treatment of hyperglycemia with oral medications and insulin. Cui and Andersen proposed that metformin should be the first-line therapy for pancreatic diabetes because of the possible risk of cancer with insulin and insulin secretagogues.

Based on the clinical characteristics of diabetes, three types can be distinguished (Table 3), although pancreatic diabetes could occur in combination with other forms. For example, in drinkers, pancreatic diabetes may be caused by chronic pancreatitis associated with chronic alcohol intake, while type 2 diabetes may occur as a result of obesity, overeating, infrequent exercise, and smoking in the same individual. Given that smoking is associated with chronic pancreatitis and type 2 diabetes, often it may be hard to differentiate between pancreatic diabetes and type 2 diabetes in actual clinical practice. Therefore, the fundamental type of diabetes may be complicated in some individuals, representing a combination of type 2 diabetes and pancreatic diabetes.

**Extrapancreatic diseases and conditions**

PEI is also common in patients with extrapancreatic diseases. Several trials have been conducted to examine possible treatments of PEI associated with extrapancreatic disease (Table 4). Although the drug used in these studies was mostly pancreatin instead of pancrelipase, the results may be meaningful in the consideration of PERT for extrapancreatic disease and conditions.

**Gastrointestinal diseases**

**Celiac disease**

Celiac disease is an inflammatory intestinal disease that causes intolerance to gluten present in foods such as wheat and rye. The clinical symptoms include diarrhea and other gastrointestinal disorders caused by maldigestion and malabsorption of nutrients and vitamins. The mainstay treatment is a gluten-free diet, which improves gastrointestinal function, corrects diarrhea, and enables weight gain. However, strict adherence to a gluten-free diet is not effective in all patients. Indeed, chronic diarrhea may persist in many patients, suggesting other factors are involved in this disease.

The prevalence of celiac disease in the general population, as assessed by screening of healthy volunteers in the US, UK, and other European countries, was 0.5%–1%. Celiac disease is frequently associated with PEI, possibly because of increased immune activity in the intestinal tract. Evans et al showed that in a study of 20 patients with celiac disease, diarrhea was improved in 19 patients given PERT at a mean dose of 45,000 lipase units/day. Leeds et al also showed that low fecal elastase content is more common in patients with celiac disease and chronic diarrhea, and that PERT in combination with a gluten-free diet reduced stool frequency from four per day to one.

**Irritable bowel syndrome**

Irritable bowel syndrome is a common functional gastrointestinal disorder that affects up to 15% of the general population.
The pathophysiology of irritable bowel syndrome is complicated, but seems to involve dysfunction of the brain–gut axis. It was reported that PEI, as assessed by low fecal elastase-1 concentrations, was detected in just 6.1% of patients who fulfilled the Rome II criteria for diarrhea-predominant irritable bowel syndrome. The association between inflammatory bowel disease and the pancreas is demonstrated in many reports showing altered pancreatic exocrine function and PEI in patients with inflammatory bowel disease. In fact, Angelini et al reported that pancreatic dysfunction is more common than is generally recognized in patients with Crohn’s disease. In their study, PERT improved clinical symptoms such as diarrhea in patients with irritable bowel syndrome. Whether PERT improves clinical symptoms such as diarrhea in patients with irritable bowel syndrome.

**Chronic inflammatory bowel disease**

Crohn’s disease and ulcerative colitis, two of the most common types of inflammatory bowel disease, are characterized by a number of extraintestinal manifestations. The causes of diarrhea in patients include exocrine pancreatic insufficiency. PERT improved stool frequency, stool consistency, and abdominal pain in patients with fecal elastase-1 concentrations < 100 μg/g stool. However, the study was conducted in an open-label manner without a placebo control group. Therefore, further studies are needed to confirm whether PERT improves clinical symptoms such as diarrhea in patients with irritable bowel syndrome.

### Table 4: Clinical trials for treatment of pancreatic exocrine insufficiency in extrapancreatic diseases and diabetes

<table>
<thead>
<tr>
<th>Authors</th>
<th>Study design, duration, and number of subjects</th>
<th>Disease/drug</th>
<th>Results</th>
<th>Adverse effects</th>
<th>Evidence level</th>
</tr>
</thead>
<tbody>
<tr>
<td>Evans et al</td>
<td>Prospective study, months to 4 years, 19 adults</td>
<td>Celiac disease/Creon (pancreatin)</td>
<td>There was an increase in fecal elastase-1 levels over time, with median of 90 μg/g at 0 months, 212 μg/g at 6 months, and 365 μg/g at follow-up (P &lt; 0.0001) in patients who received PERT throughout</td>
<td>Overall, 8/19 patients had discontinued supplementation because their diarrhea had improved; only 1/11 reported no symptomatic benefit</td>
<td>3</td>
</tr>
<tr>
<td>Leeds et al</td>
<td>Open-label, up to 2 years, 20 adults</td>
<td>Celiac disease</td>
<td>Unknown</td>
<td>In 18 of 20, stool frequency reduced following pancreatic enzyme supplementation from four daily to one daily (P &lt; 0.001); no weight increase was observed; all patients had duodenal histological improvement</td>
<td>No description regarding TEAEs</td>
</tr>
<tr>
<td>Leeds et al</td>
<td>Open-label, 6 and 12 weeks, 34 adults</td>
<td>Irritable bowel syndrome</td>
<td>Creon</td>
<td>Improvements in stool frequency (from median 6 to less than 2 daily, P &lt; 0.001), stool consistency (P &lt; 0.001), and abdominal pain (P = 0.003) were observed in patients with fecal elastase-1 levels less than 100 μg/g stool</td>
<td>No major side effects were reported; some patients felt nausea but no patients stopped therapy</td>
</tr>
<tr>
<td>Ewald et al</td>
<td>DBRPC, 16 week, 80 adults (Creon 39 and placebo 41)</td>
<td>Type 1 diabetes</td>
<td>Creon (pancreatin)</td>
<td>There were no significant differences between pancreatin group and placebo group concerning HbA1c, fasting glucose levels, and 2-hour glucose levels after oral glucose tolerance test, clinical parameters</td>
<td>TEAEs occurred in 33 patients (84.6%) in pancreatin group and in 35 (85.4%) in placebo group; most frequent adverse events were headache, infection, diarrhea, and dyspepsia</td>
</tr>
<tr>
<td>Knop et al</td>
<td>Open-label, postprandial (test meal) response, 8 male adults</td>
<td>Chronic pancreatitis</td>
<td>Creon</td>
<td>The postprandial responses of total GLP-1 and total GIP were increased (both P = 0.01) along with increased plasma insulin and total insulin secretion after pancreatic enzyme substitution</td>
<td>No description regarding TEAEs</td>
</tr>
</tbody>
</table>

**Abbreviations:** DBRPC, double-blind, randomized, placebo-controlled trial; TEAEs, treatment-emergent adverse events; GLP-1, glucagon-like peptide-1; GIP, gastric inhibitory polypeptide; HbA1c, glycosylated hemoglobin.
11/27 patients had bicarbonate plus enzyme insufficiency or enzyme insufficiency alone, while 18/27 patients had isolated decreased lipase levels. Pancreatic insufficiency is a frequent complication in patients with inflammatory bowel disease, particularly in patients with loose stools, a large number of daily bowel movements, and a history of surgery.77 These findings point towards a high risk of pancreatitis in patients with inflammatory bowel disease. Awareness of this risk could significantly improve the management of inflammatory bowel disease.78

Zollinger–Ellison syndrome and gastrectomy

Zollinger–Ellison syndrome is a rare disease characterized by hypersecretion of gastrin from non-beta cell islet tumors in the pancreas, leading to refractory peptic ulcers and diarrhea caused by inactivation of pancreatic enzymes. Proton pump inhibitor therapy is effective in controlling gastric acid hypersecretion,79 and reduces the morbidity and potential mortality associated with this syndrome.80 Interestingly, Zollinger–Ellison syndrome mimics PEI in terms of clinical symptom, probably via gastrointestinal dysfunction. Therefore, in patients who experience no improvement in diarrhea or PEI following PERT, Zollinger–Ellison syndrome or multiple endocrine neoplasia type 1 should be considered as potential causes.

PEI is commonly observed after pancreatic resection and after partial or total gastrectomy.81 PERT is indicated for patients with clinically evident steatorrhea, weight loss, or maligestion-related symptoms after gastric or duodenal surgery.82 However, relatively few studies have focused on these issues, so treatment with pancrelipase gastrectomy should be considered on an individual patient basis.

Type 1 and type 2 diabetes

As described above, pancreatic diabetes is a type of pancreatic disease. Numerous clinical studies have actually shown that as many as 50% of patients with type 1 diabetes and 20% of patients with type 2 diabetes had clinical features of PEI.13 Furthermore, intriguingly, Nues et al.13 showed that, compared with lean patients with diabetes, obese patients (body mass index > 25.0 kg/m²) with diabetes were at increased risk for PEI, and that steatorrhea was detected in approximately one-third of obese patients with diabetes and low fecal elastase-1 levels. The etiology of the “traditional” forms of diabetes, particularly type 2 diabetes, differs from that of pancreatic diabetes. Nevertheless, up to 9% of all cases of diabetes were found to be caused by pancreatic diabetes, much higher than is commonly believed, suggesting that some cases of pancreatic diabetes are misdiagnosed type 1 or type 2 diabetes.59,60

Although the mechanism by which people with diabetes develop PEI is largely unclear, one plausible reason is that insulin has a trophic effect on pancreatic acinar cells.83 Thus, the lack of or reduced secretion of insulin in the pancreas may lead to inactivity of acinar cells, inducing atrophic changes that subsequently reduce exocrine function, resulting in PEI. In addition, in type 2 diabetes, insulin resistance and resultant hyperinsulinemia might downregulate insulin receptor expression in acinar cells.84 Diabetic neuropathy may also induce functional and morphological alterations that could result in PEI, as proposed by Hardit et al. Alternatively, an antibody against islet cells can cross-react with acinar cells and disrupt its functions.

Taken together, PEI appears to be a complication of type 1 and type 2 diabetes. Given that PEI may be a complication of diabetes and that hyperglycemia and/or insulin inactivity (caused by hypoinsulinemia or insulin resistance) induce pancreatic exocrine dysfunction and the development of PEI, appropriate antidiabetic therapies are important, irrespective of the type of diabetes (Figure 1).

In the context of PERT, a 16-week randomized study in 80 patients with type 1 diabetes and low fecal elastase-1 concentrations found no significant differences in HbA1c, fasting glucose levels, clinical parameters, or safety parameters between patients treated with Creon (4 × 10,000 Fédération Internationale Pharmaceutique units) or placebo.85 However, the frequency of hypoglycemia was lower in patients treated with Creon. Unfortunately, no other clinical study has examined the potential utility of PERT for the management of PEI in patients with diabetes. Consequently, until further evidence is reported, PERT with pancrelipase should be considered on an individual patient basis, with appropriate assessment of PEI and abnormal glucose metabolism.

Another factor that should be considered is that PERT is likely to increase the effects of incretins, irrespective of glycemic status.86 Indeed, in that study, the response of total glucagon-like peptide-1 was increased after pancreatic enzyme substitution (Creon, pancreatin) and was associated with increased plasma insulin levels and total insulin secretion without changes in the area under the plasma glucose concentration-time curve. These results suggest that PERT may improve glucose metabolism by restoring the activity of incretins, such as glucagon-like peptide-1, in patients with chronic pancreatitis. Unfortunately, it is still unknown whether diabetes secondary to conditions associated with hypersecretion of glucocorticoid or thyroid horomones could result in the development of PEI, or whether PERT could be beneficial in these settings.
Aging is associated with changes in pancreatic enzyme secretion. For example, Laugier et al. reported that concentrations of pancreatic enzymes decreased linearly with age from 30 years of age in apparently healthy individuals. Vellas et al. reported that bicarbonate, lipase, and chymotrypsin concentrations in elderly subjects with a mean age of 72 years were significantly reduced by 17%, 15%, and 23%, respectively ($P < 0.05$), as compared with those in younger subjects (mean age 36 years). Rothenbacher et al. showed that prevalence of PEI defined as low elastase-1 concentrations, increases with age. PEI was detected in 6.0% of patients aged 50–54 years, but in 13.4% for those aged 70–75 years ($P = 0.005$). Additionally, the prevalence of PEI seemed to be higher in men than in women. They also found that smoking was an independent risk factor for PEI, whereas the use of an angiotensin-converting enzyme inhibitor was protective against PEI. In another study, approximately 20% of apparently healthy individuals ≥ 60 years of age without history of gastrointestinal disorder, surgery, or diabetes had PEI defined, as fecal elastase-1 concentrations of $< 100 \mu g/g$.

**Conclusion**

In patients with pancreatic diseases, particularly chronic pancreatitis and cystic fibrosis, PERT with approved pancrelipase products should be considered the first-line therapy for PEI. To achieve adequate clinical effects with these agents, a gradual increase in dosage and coadministration of a gastric acid suppressor may be necessary. However, large long-term studies are needed to explore the optimal treatment of patients with PEI, and to examine the effects of PERT with pancrelipase products on mortality and morbidity. PERT may also be useful in other diseases associated with PEI, including extrapancreatic diseases, such as gastrointestinal diseases and diabetes (except pancreatic diabetes), and in elderly subjects. Although we are still awaiting robust clinical evidence, the use of PERT should be considered on an individual patient basis. In terms of the pancreatic exocrine–endocrine relationship, clinicians need to become more aware of the risk of pancreatic diabetes, another crucial complication of pancreas disease associated with poor morbidity and mortality. Further studies are needed to explore the clinical relevance and appropriate treatment of this disorder.

**Disclosure**

The authors report no conflicts of interest in this work.

**References**


